How much funding has ArsenalBio raised?

ArsenalBio has raised $955.0M in total funding, most recently a Series C round.

Who are ArsenalBio's investors?

ArsenalBio's investors include ARCH Venture Partners, Bristol Myers Squibb, Kleiner Perkins, Westlake Village BioPartners, Milky Way Investments Group, nVentures.

When was ArsenalBio founded?

ArsenalBio was founded in 2019.

Where is ArsenalBio headquartered?

ArsenalBio is headquartered in San Francisco, California, United States.

What industry is ArsenalBio in?

ArsenalBio operates in Biotech, Life Sciences, Therapeutics, Healthcare.

How many employees does ArsenalBio have?

ArsenalBio has 201-500 employees.

ArsenalBio

formerly Arsenal Biosciences

Engineering Hope®

San Francisco, United States · Founded 2019 · $955.0M raised

Headquarters: San Francisco, California
Employees: 201–500
Founded: 2019
Business Model: B2B

Website: arsenalbio.com
Total Funding: $955.0M
Last Round: $325.0M Series CSep 2024
Rounds: 4

About

ArsenalBio is a clinical-stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors. Using a synthetic biology toolkit, the company genetically programs patients' T cells to eradicate solid tumors and has an ongoing multi-program collaboration with Bristol Myers Squibb to advance next-generation T-cell therapies.

Summary

ArsenalBio is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $955.0M in total across 4 rounds, most recently a $325.0M Series C round in Sep 2024. Investors include ARCH Venture Partners, Bristol Myers Squibb and Kleiner Perkins.

LinkedIn X (Twitter)